Novo Nordisk Inc. is a major pharmaceutical company that develops drugs and treatments. Its lobbying filings show it focuses on Medicare and Medicaid issues, especially the coverage of obesity medicines. It reported $120,000 in lobbying and used Public Strategies Washington, Inc. to represent its interests in Washington, D.C.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
mr PATRICK JOHN O'NEILL
The latest disclosures for this client.
PUBLIC STRATEGIES WASHINGTON, INC.
1TYPUBLIC STRATEGIES WASHINGTON, INC.
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
PUBLIC STRATEGIES WASHINGTON, INC.
ABBIE SORRENDINO
PUBLIC STRATEGIES WASHINGTON, INC.
ms ANGELA SMITH ZIMMERMAN
PUBLIC STRATEGIES WASHINGTON, INC.
A.J. WOJCIAK
PUBLIC STRATEGIES WASHINGTON, INC.
PUBLIC STRATEGIES WASHINGTON, INC.
Q3PUBLIC STRATEGIES WASHINGTON, INC.
Q2PUBLIC STRATEGIES WASHINGTON, INC.
Q1